Chengdu Endor Biological Engineering Technology

Chengdu Endor Biological Engineering Technology is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative recombinant protein drugs. The company's lead product, Novaferon (recombinant human interferon-like protein), is a first-in-class biologic approved by the NMPA for the treatment of chronic hepatitis B. Endor leverages its proprietary protein engineering technology to develop cytokines with improved therapeutic indices compared to traditional interferons. The company maintains a vertically integrated structure with R&D and GMP-compliant manufacturing capabilities in Chengdu. Beyond its commercial success in infectious diseases, the company is advancing clinical trials for Novaferon in various oncology indications, including melanoma.